Name | Rimiducid |
Description | Rimiducid is a lipid-permeable tacrolimus analogue, homodimerizing an analogue of human protein fkbp12 and binding to wild-type fkbp12 with 1000-fold lower affinity. Rimiducid is a dimerizer agent that acts by cross-linking the FKBP domains. It dimerizes the Caspase 9 suicide switch and rapidly induces apoptosis. |
In vitro | AP1903, a bivalent 'dimerizer' drug that binds FKBP and induces Fas cross-linking.?A single 2-hour treatment eliminated approximately 80% of T cells, and multiple exposures induced further apoptosis.?T cells were eliminated regardless of their proliferation state, suggesting that the AP1903/Fas system, which contains only human components, is a promising alternative to HSV-tk for treating GVHD[2]. |
In vivo | Constitutive hGH secretion provides a convenient and accurate way to monitor the number of viable cells in vivo because hGH has a serum half-life of only ≈3 min in mice. Over 3 consecutive days, we implanted these cells i.m. into nude mice, and treated the animals i.v. with various doses of Rimiducid, and then determined serum hGH levels as a measure of the number of surviving cells. Rimiducid (AP1903; i.v.,0.01, 0.1, 1, 10, and 100 mg/kg) elicits a dose-dependent decrease in serum human GH levels, with a half-maximal effective dose of 0.4±0.1 mg/kg[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 50 mg/mL (35.42 mM), Sonication is recommended.
|
Keywords | AP1903 | Inhibitor | Apoptosis | FKBP | Rimiducid | AP-1903 | AP 1903 | inhibit | FK506-binding protein |
Inhibitors Related | Stavudine | 5-Fluorouracil | Kaempferol | Myricetin | Meclizine dihydrochloride | Sodium 4-phenylbutyrate | L-Ascorbic acid | Metronidazole | Sorafenib | Tributyrin | Salicylic acid | Oleic acid |